KI
NBIX icon

Kula Investments’s Neurocrine Biosciences NBIX Stock Holding History

Kula Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$510K Buy
5,041
+1,861
+59% +$194K 0.13% 296
2022
Q4 		$380K Buy
+3,180
New +$372K 0.11% 297

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Kula Investments's NBIX Position: Q1 2023 in Review

Kula Investments increased its Neurocrine Biosciences (NBIX) stake by 59% in Q1 2023, buying an estimated $194K and bringing the position to 5,041 shares worth $510K. The position accounts for 0.13% of the portfolio, ranked #296.

Kula Investments first reported a position in NBIX in Q4 2022 and has held it in 2 quarters since. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

  • Kula Investments held 5,041 shares of Neurocrine Biosciences worth $510K as of Q1 2023.
  • Kula Investments bought 1,861 Neurocrine Biosciences shares in Q1 2023, an estimated $194K.
  • Neurocrine Biosciences made up 0.13% of Kula Investments's portfolio in Q1 2023, its #296 holding.
  • Kula Investments first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 2 quarters since.
  • 486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on Kula Investments's 13F filing for Q1 2023, filed 15 May 2023.